GlaxoSmithKline PLC (GSK.L) News| Reuters.com
Edition:
United States

GlaxoSmithKline PLC (GSK.L)

GSK.L on London Stock Exchange

1,489.02GBp
4:59am EDT
Change (% chg)

1.00p (+0.07%)
Prev Close
1,488.00p
Open
1,516.50p
Day's High
1,516.50p
Day's Low
1,487.00p
Volume
2,552,482
Avg. Vol
8,385,820
52-wk High
1,532.10p
52-wk Low
1,210.27p

Select another date:

Fri, Jun 24 2016

BRIEF-Mylan launches generic version of GSK's avodart capsules

* U.S. launch of Dutasteride capsules, 0.5 mg, generic version of GlaxoSmithKline's avodart capsules Source text for Eikon: Further company coverage:

BRIEF-Glaxosmithkline says though the eu referendum result creates uncertainty and potentially complexity ... It does not currently anticipate a material adverse impact on the business, group's results or financial position

* Glaxosmithkline says though the eu referendum result creates uncertainty and potentially complexity ... It does not currently anticipate a material adverse impact on the business, group's results or financial position Source text for Eikon: Further company coverage:

GAVI alliance offers matched funds for GSK malaria vaccine pilot

LONDON, June 23 The GAVI global vaccine alliance has offered funding of up to $27.5 million for pilot tests of GlaxoSmithKline's first-generation malaria vaccine, but only if other organisations promise to match that commitment.

BRIEF-Theravance Biopharma highlights positive results from phase 3 fulfil study of closed triple announced by Glaxosmithkline, Innoviva

* Highlights positive top-line results from pivotal phase 3 fulfil study of closed triple announced by Glaxosmithkline, Innoviva

GlaxoSmithKline says lung drug meets late-stage study goals

Drugmaker GlaxoSmithKline Plc said its experimental combination therapy for a chronic lung problem met the main goal of a late-stage study, allowing the company to apply for marketing of the drug by the end of 2016.

GlaxoSmithKline says lung drug meets late-stage study goals

June 20 Drugmaker GlaxoSmithKline Plc said its experimental combination therapy for a chronic lung problem met the main goal of a late-stage study, allowing the company to apply for marketing of the drug by the end of 2016.

BRIEF-GlaxoSmithKline says lung drug meets late-stage study goals

* Fulfil study shows superiority of closed triple combination therapy ff/umec/vi versus symbicort turbohaler

Factory snag hits GSK supply, causing Danish anaesthetic shortage

LONDON Manufacturing problems at a factory in Italy have disrupted production of some GlaxoSmithKline medicines, leading to shortages of a commonly used opioid anaesthetic in Denmark.

Factory snag hits GSK supply, causing Danish anaesthetic shortage

LONDON, June 17 Manufacturing problems at a factory in Italy have disrupted production of some GlaxoSmithKline medicines, leading to shortages of a commonly used opioid anaesthetic in Denmark.

GlaxoSmithKline says vaccines business head to retire

Drugmaker GlaxoSmithKline Plc said Moncef Slaoui, chairman of its vaccines business, would retire next year.

Select another date: